Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 165 Shares of Stock

Key Points

• Executive sale: EVP Michael Feld sold 165 BDX shares for approximately $31,101 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 0.83% to 19,720 shares. He also sold 75 shares each in June and July.
• Operating performance: Becton Dickinson reported quarterly EPS of $3.23, exceeding estimates by $0.09, while revenue rose 5.4% year over year to $4.98 billion. The company maintained fiscal 2026 EPS guidance of $12.62–$12.72.
• Stock and outlook: Shares fell 1.1% to $188.11, near their 52-week high, while analysts’ consensus rating remained “Hold” with a $185.67 price target. The company also declared a quarterly dividend of $1.05 per share, implying a 2.2% annualized yield.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $157.13, for a total value of $11,784.75.
• On Friday, June 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $152.80, for a total transaction of $11,460.00.

Becton, Dickinson and Company Trading Down 1.1%

Becton, Dickinson and Company stock traded down $2.10 during midday trading on Thursday, hitting $188.11. 1,353,617 shares of the stock were exchanged, compared to its average volume of 2,623,575. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The stock's 50-day simple moving average is $164.35 and its 200 day simple moving average is $160.49. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The stock has a market capitalization of $51.83 billion, a price-to-earnings ratio of 56.66, a PEG ratio of 13.38 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business's revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is currently 126.51%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Imprint Wealth LLC purchased a new position in Becton, Dickinson and Company in the 3rd quarter valued at approximately $25,000. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $26,000. Meeder Asset Management Inc. raised its stake in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 102 shares in the last quarter. Main Street Group LTD purchased a new position in Becton, Dickinson and Company in the first quarter valued at $29,000. Finally, Bell Investment Advisors Inc purchased a new position in Becton, Dickinson and Company in the second quarter valued at $29,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Jefferies Financial Group reaffirmed a "buy" rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Bank of America decreased their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Royal Bank Of Canada boosted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research report on Thursday, August 13th. Finally, Barclays upped their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a research note on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source